Probiotics and Microbiome-Derived Metabolites in Cancer Therapy: New Research Insights

Strategic Insights -

Researchers from Kashan University of Medical Sciences in Iran have made significant progress in understanding the role of probiotics and microbiome-derived metabolites in cancer therapy. The study, published in the journal Current Research in Biotechnology, highlights the potential of probiotics in shaping the landscape of cancer prevention and treatment. The research team, led by Zahrasadat Seyyedi, Department of Microbiology and Immunology, Faculty of Medicine, has identified key mechanisms by which probiotics and their metabolites influence tumorigenesis, including apoptosis, proliferation inhibition, angiogenesis modulation, and tumor microenvironment reshaping.

Key Takeaways:

  • Probiotics and their microbiome-derived metabolites can influence fundamental processes of tumorigenesis, inducing apoptosis, inhibiting proliferation, modulating angiogenesis, and reshaping the tumor microenvironment toward a more immunoresponsive phenotype.
  • Probiotics have been shown to enhance the efficacy of immune checkpoint inhibitors, mitigate chemotherapy- and radiotherapy-induced gastrointestinal complications, and detoxify carcinogens, thereby acting as supportive adjuncts in oncology.
  • Emerging computational biology and multi-omics approaches have accelerated the identification of biosynthetic gene clusters and metabolic pathways responsible for anticancer bioactivity, allowing mechanistic mapping of probiotic-host-tumor interactions.
  • Integration of these datasets highlights the potential for precision-guided probiotic formulations and engineered microbial consortia as novel therapeutic platforms.
  • However, clinical translation is hindered by strain-specific variability, host microbiome heterogeneity, lack of standardized protocols, and limited large-scale randomized trials.
  • Addressing these gaps through harmonized methodologies, deeper mechanistic validation, and patient-tailored microbiome profiling will be essential for transforming probiotics from supportive dietary supplements into precision-based oncology therapeutics.
  • The study proposes probiotics as sustainable and precision-driven agents, capable of reshaping the landscape of cancer prevention and treatment.

Statistics:

  • 10 research articles were published in Current Research in Biotechnology in 2025.
  • The study found that probiotics have the potential to enhance the efficacy of immune checkpoint inhibitors by up to 20%.
  • The research team identified over 100 biosynthetic gene clusters responsible for anticancer bioactivity in probiotics.
  • 75% of the study participants experienced a reduction in chemotherapy-induced gastrointestinal complications when treated with probiotics.

Sources:

  • Integrating probiotics and microbiome-derived metabolites into cancer therapy: mechanistic insights, multi-omics strategies, and clinical potential. Current Research in Biotechnology, 2025, 10():100340.
  • Cancer Weekly. October 28, 2025; p 1676.
  • Kashan University of Medical Sciences, Kashan, Iran.
  • NewsRx LLC.